JP2021098728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021098728A5 JP2021098728A5 JP2021037000A JP2021037000A JP2021098728A5 JP 2021098728 A5 JP2021098728 A5 JP 2021098728A5 JP 2021037000 A JP2021037000 A JP 2021037000A JP 2021037000 A JP2021037000 A JP 2021037000A JP 2021098728 A5 JP2021098728 A5 JP 2021098728A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- orally administered
- acceptable excipient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023032872A JP2023060145A (ja) | 2018-05-14 | 2023-03-03 | Ｍｃｌ－１阻害剤 |
| JP2025080314A JP7792036B2 (ja) | 2018-05-14 | 2025-05-13 | Ｍｃｌ－１阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671306P | 2018-05-14 | 2018-05-14 | |
| US62/671,306 | 2018-05-14 | ||
| US201862749918P | 2018-10-24 | 2018-10-24 | |
| US62/749,918 | 2018-10-24 | ||
| JP2020564228A JP6899975B2 (ja) | 2018-05-14 | 2019-05-13 | Ｍｃｌ−１阻害剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564228A Division JP6899975B2 (ja) | 2018-05-14 | 2019-05-13 | Ｍｃｌ−１阻害剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023032872A Division JP2023060145A (ja) | 2018-05-14 | 2023-03-03 | Ｍｃｌ－１阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021098728A JP2021098728A (ja) | 2021-07-01 |
| JP2021098728A5 true JP2021098728A5 (enExample) | 2022-10-12 |
| JP7240431B2 JP7240431B2 (ja) | 2023-03-15 |
Family
ID=66770559
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564228A Active JP6899975B2 (ja) | 2018-05-14 | 2019-05-13 | Ｍｃｌ−１阻害剤 |
| JP2021037000A Active JP7240431B2 (ja) | 2018-05-14 | 2021-03-09 | Ｍｃｌ－１阻害剤 |
| JP2023032872A Pending JP2023060145A (ja) | 2018-05-14 | 2023-03-03 | Ｍｃｌ－１阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564228A Active JP6899975B2 (ja) | 2018-05-14 | 2019-05-13 | Ｍｃｌ−１阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023032872A Pending JP2023060145A (ja) | 2018-05-14 | 2023-03-03 | Ｍｃｌ－１阻害剤 |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US10703733B2 (enExample) |
| EP (2) | EP4029868A1 (enExample) |
| JP (3) | JP6899975B2 (enExample) |
| KR (4) | KR102732008B1 (enExample) |
| CN (2) | CN112118845B (enExample) |
| AU (3) | AU2019269391B2 (enExample) |
| BR (1) | BR112020021648A2 (enExample) |
| CA (1) | CA3099152C (enExample) |
| CL (1) | CL2020002919A1 (enExample) |
| CO (1) | CO2020014009A2 (enExample) |
| CR (1) | CR20200544A (enExample) |
| CY (1) | CY1125065T1 (enExample) |
| DK (1) | DK3793565T3 (enExample) |
| ES (1) | ES2907923T3 (enExample) |
| HR (1) | HRP20220215T1 (enExample) |
| HU (1) | HUE057852T2 (enExample) |
| IL (2) | IL291430B2 (enExample) |
| LT (1) | LT3793565T (enExample) |
| MX (1) | MX2020012137A (enExample) |
| MY (1) | MY198871A (enExample) |
| PE (1) | PE20210004A1 (enExample) |
| PH (1) | PH12020551881A1 (enExample) |
| PL (1) | PL3793565T3 (enExample) |
| PT (1) | PT3793565T (enExample) |
| SG (1) | SG11202010964VA (enExample) |
| SI (1) | SI3793565T1 (enExample) |
| TW (4) | TWI813957B (enExample) |
| UA (1) | UA125163C2 (enExample) |
| WO (1) | WO2019222112A1 (enExample) |
| ZA (1) | ZA202007007B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102732008B1 (ko) | 2018-05-14 | 2024-11-20 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 억제제 |
| EP3643711A1 (en) | 2018-10-24 | 2020-04-29 | Bayer Animal Health GmbH | New anthelmintic compounds |
| ES2987630T3 (es) | 2019-07-09 | 2024-11-15 | Janssen Pharmaceutica Nv | Derivados de espirociclos macrocíclicos como inhibidores de MCL-1 |
| US11795223B2 (en) | 2019-10-18 | 2023-10-24 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| MX2022005123A (es) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| US11325891B2 (en) | 2019-11-26 | 2022-05-10 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| US20230212191A1 (en) * | 2020-04-16 | 2023-07-06 | Prelude Therapeutics, Incorporated | Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
| US20230219906A1 (en) | 2020-06-10 | 2023-07-13 | Janssen Pharmaceutica Nv | Macrocyclic-2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1 |
| CN116457334A (zh) * | 2020-11-19 | 2023-07-18 | 吉利德科学公司 | 用于制备大环mcl1抑制剂的方法和中间体 |
| ES3026771T3 (en) | 2020-12-17 | 2025-06-12 | Janssen Pharmaceutica Nv | Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| AU2022267722A1 (en) | 2021-04-26 | 2023-12-14 | Janssen Pharmaceutica Nv | Macrocyclic 2-allyltetrahydrofurans as inhibitors of mcl-1 |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| WO2022261310A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| CN117651554A (zh) * | 2021-06-11 | 2024-03-05 | 吉利德科学公司 | Mcl-1抑制剂与抗癌剂的组合 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2024005928A (es) | 2021-11-16 | 2024-06-04 | Janssen Pharmaceutica Nv | 2-amino-but-3-enamidas macrociclicas como inhibidores de mcl-1. |
| JP2025509662A (ja) | 2022-03-24 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| US12162896B2 (en) * | 2022-05-04 | 2024-12-10 | Gilead Sciences, Inc. | Salts and polymorphs of certain MCL-1 inhibitors |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| US20090142345A1 (en) | 2005-03-15 | 2009-06-04 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| CN110372795A (zh) | 2007-08-02 | 2019-10-25 | 吉利德生物制剂公司 | Lox和loxl2抑制剂及其应用 |
| PL2310509T3 (pl) | 2008-07-21 | 2015-08-31 | Apogenix Ag | Jednołańcuchowe cząsteczki TNFSF |
| US8652843B2 (en) | 2008-08-12 | 2014-02-18 | Oncomed Pharmaceuticals, Inc. | DDR1-binding agents and methods of use thereof |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| RU2015108348A (ru) | 2010-02-04 | 2015-07-20 | Джилид Байолоджикс, Инк. | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| AU2011293125B2 (en) | 2010-08-27 | 2015-02-05 | Gilead Sciences, Inc. | Antibodies to matrix metalloproteinase 9 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
| US9550835B2 (en) | 2011-08-23 | 2017-01-24 | Chugai Seiyaku Kabushiki Kaisha | Anti-DDR1 antibody having anti-tumor activity |
| GB201115529D0 (en) | 2011-09-08 | 2011-10-26 | Imp Innovations Ltd | Antibodies, uses and methods |
| CA2850763A1 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| WO2013116562A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
| UY35044A (es) | 2012-09-24 | 2014-04-30 | Gilead Sciences Inc | ANTICUERPOS ANTI-dDr1 |
| US9029384B2 (en) | 2012-12-21 | 2015-05-12 | Gilead Calistoga, LLC. | Phosphatidylinositol 3-kinase inhibitors |
| AU2013364068B2 (en) | 2012-12-21 | 2016-10-20 | Gilead Calistoga Llc | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| TWI644909B (zh) | 2013-06-14 | 2018-12-21 | 基利科學股份有限公司 | 磷脂酸肌醇３－激酶抑制劑 |
| MX2016001304A (es) | 2013-07-30 | 2016-04-07 | Gilead Connecticut Inc | Polimorfo de inhibidores de syk. |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| CA2943815C (en) * | 2014-03-27 | 2023-04-04 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| SG11201608393TA (en) | 2014-04-10 | 2016-11-29 | Seattle Children S Hospital Dba Seattle Children S Res Inst | Transgene genetic tags and methods of use |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| JO3474B1 (ar) * | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| CN106715419A (zh) | 2014-09-26 | 2017-05-24 | 吉利德科学公司 | 用作tank‑结合激酶抑制剂化合物的氨基三嗪衍生物 |
| EP3227323B1 (en) | 2014-12-03 | 2020-08-05 | Juno Therapeutics, Inc. | Methods and compositions for adoptive cell therapy |
| CA2966234A1 (en) | 2014-12-15 | 2016-06-23 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| WO2016186967A1 (en) | 2015-05-15 | 2016-11-24 | Gilead Sciences, Inc. | Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase |
| WO2016196388A1 (en) | 2015-05-29 | 2016-12-08 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
| MX2018003353A (es) | 2015-09-17 | 2018-09-17 | Novartis Ag | Terapias con celulas cart con una eficacia mejorada. |
| US11306107B2 (en) | 2016-02-25 | 2022-04-19 | Amgen Inc. | Compounds that inhibit MCL-1 protein |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| EP3668878B1 (en) | 2017-08-18 | 2025-05-21 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
| US11279712B2 (en) | 2017-08-29 | 2022-03-22 | Amgen Inc. | Macrocyclic compounds that inhibit MCL-1 protein |
| CA3079081A1 (en) | 2017-10-19 | 2019-04-25 | Michael D. Bartberger | Benzimidazole derivatives and their uses |
| MA54985A (fr) | 2018-03-05 | 2021-12-29 | Amgen Inc | Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 |
| EP3794009A1 (en) | 2018-05-14 | 2021-03-24 | Reata Pharmaceuticals, Inc. | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
| KR102732008B1 (ko) | 2018-05-14 | 2024-11-20 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 억제제 |
| SG11202011228TA (en) | 2018-05-15 | 2020-12-30 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
| SG11202100158WA (en) | 2018-07-24 | 2021-02-25 | Epizyme Inc | Pyridin-2-one compounds useful as smarca2 antagonists |
| JP2022506973A (ja) | 2018-11-09 | 2022-01-17 | プレリュード セラピューティクス，インコーポレイティド | 骨髄性細胞白血病－１（ｍｃｌ－１）タンパク質の阻害剤としてのスピロ－スルホンアミド誘導体 |
| WO2020147802A1 (en) | 2019-01-18 | 2020-07-23 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic spiroethers as mcl-1 inhibitors |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| US11325891B2 (en) | 2019-11-26 | 2022-05-10 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| JP2021161114A (ja) | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Ｍｃｌ−１化合物のメチル化 |
| CA3181214A1 (en) | 2020-05-06 | 2021-11-11 | Amgen Inc. | Synthesis of vinylic protected alcohol intermediates |
| TWI827924B (zh) | 2020-05-06 | 2024-01-01 | 美商安進公司 | 大環Mcl-1抑制劑中間體的閉環合成 |
| US20230219906A1 (en) | 2020-06-10 | 2023-07-13 | Janssen Pharmaceutica Nv | Macrocyclic-2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1 |
| EP4178677A1 (en) | 2020-07-08 | 2023-05-17 | JANSSEN Pharmaceutica NV | Macrocyclic ether containing indole derivatives as inhibitors of mcl-1 |
| CN116457334A (zh) | 2020-11-19 | 2023-07-18 | 吉利德科学公司 | 用于制备大环mcl1抑制剂的方法和中间体 |
-
2019
- 2019-05-13 KR KR1020247015778A patent/KR102732008B1/ko active Active
- 2019-05-13 EP EP21218221.6A patent/EP4029868A1/en active Pending
- 2019-05-13 EP EP19728793.1A patent/EP3793565B1/en active Active
- 2019-05-13 SI SI201930181T patent/SI3793565T1/sl unknown
- 2019-05-13 PT PT197287931T patent/PT3793565T/pt unknown
- 2019-05-13 HR HRP20220215TT patent/HRP20220215T1/hr unknown
- 2019-05-13 UA UAA202006695A patent/UA125163C2/uk unknown
- 2019-05-13 CR CR20200544A patent/CR20200544A/es unknown
- 2019-05-13 PL PL19728793T patent/PL3793565T3/pl unknown
- 2019-05-13 CA CA3099152A patent/CA3099152C/en active Active
- 2019-05-13 BR BR112020021648-8A patent/BR112020021648A2/pt unknown
- 2019-05-13 PE PE2020001829A patent/PE20210004A1/es unknown
- 2019-05-13 LT LTEPPCT/US2019/032053T patent/LT3793565T/lt unknown
- 2019-05-13 KR KR1020247038029A patent/KR20240165483A/ko active Pending
- 2019-05-13 CN CN201980032695.2A patent/CN112118845B/zh active Active
- 2019-05-13 IL IL291430A patent/IL291430B2/en unknown
- 2019-05-13 WO PCT/US2019/032053 patent/WO2019222112A1/en not_active Ceased
- 2019-05-13 JP JP2020564228A patent/JP6899975B2/ja active Active
- 2019-05-13 US US16/410,457 patent/US10703733B2/en active Active
- 2019-05-13 MY MYPI2020005671A patent/MY198871A/en unknown
- 2019-05-13 ES ES19728793T patent/ES2907923T3/es active Active
- 2019-05-13 KR KR1020207035485A patent/KR102551319B1/ko active Active
- 2019-05-13 HU HUE19728793A patent/HUE057852T2/hu unknown
- 2019-05-13 CN CN202310897123.9A patent/CN117304130A/zh active Pending
- 2019-05-13 DK DK19728793.1T patent/DK3793565T3/da active
- 2019-05-13 MX MX2020012137A patent/MX2020012137A/es unknown
- 2019-05-13 SG SG11202010964VA patent/SG11202010964VA/en unknown
- 2019-05-13 AU AU2019269391A patent/AU2019269391B2/en active Active
- 2019-05-13 KR KR1020237022152A patent/KR102666717B1/ko active Active
- 2019-05-14 TW TW110107128A patent/TWI813957B/zh active
- 2019-05-14 TW TW108116508A patent/TWI719478B/zh active
- 2019-05-14 TW TW112131732A patent/TWI844454B/zh active
- 2019-05-14 TW TW113116186A patent/TW202506687A/zh unknown
-
2020
- 2020-04-23 US US16/857,021 patent/US10988451B2/en active Active
- 2020-10-27 IL IL278336A patent/IL278336B/en unknown
- 2020-11-03 PH PH12020551881A patent/PH12020551881A1/en unknown
- 2020-11-10 CL CL2020002919A patent/CL2020002919A1/es unknown
- 2020-11-10 ZA ZA2020/07007A patent/ZA202007007B/en unknown
- 2020-11-10 CO CONC2020/0014009A patent/CO2020014009A2/es unknown
-
2021
- 2021-02-09 US US17/171,201 patent/US11643400B2/en active Active
- 2021-03-09 JP JP2021037000A patent/JP7240431B2/ja active Active
- 2021-05-25 AU AU2021203373A patent/AU2021203373B2/en active Active
-
2022
- 2022-03-16 CY CY20221100208T patent/CY1125065T1/el unknown
-
2023
- 2023-03-03 JP JP2023032872A patent/JP2023060145A/ja active Pending
- 2023-03-09 US US18/181,336 patent/US12162844B2/en active Active
- 2023-11-24 AU AU2023270332A patent/AU2023270332B2/en active Active
-
2024
- 2024-10-17 US US18/918,629 patent/US20250154116A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021098728A5 (enExample) | ||
| JP2022009090A5 (enExample) | ||
| JPWO2021121367A5 (enExample) | ||
| JP2024133475A5 (enExample) | ||
| JP2023002662A5 (enExample) | ||
| JP2024133474A5 (enExample) | ||
| JP2022191257A5 (enExample) | ||
| JP2015523397A5 (enExample) | ||
| JP2019503365A5 (enExample) | ||
| JP2013522212A5 (enExample) | ||
| JP2018507914A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2018521121A5 (enExample) | ||
| JP2023115271A5 (enExample) | ||
| JP2019533660A5 (enExample) | ||
| JP2008536853A5 (enExample) | ||
| JPWO2021214019A5 (enExample) | ||
| JP2023102787A5 (enExample) | ||
| RU2017124371A (ru) | Комбинация производного 6-оксо-1,6-дигидро-пиридазина, обладающего противораковой активностью, с производным хиназолина | |
| JP2014534229A5 (enExample) | ||
| JPWO2021116872A5 (enExample) | ||
| RU2018119085A (ru) | Схема введения ингибитора фосфатидилинозитол-3-киназы | |
| JP2019535830A5 (enExample) | ||
| JPWO2021087136A5 (enExample) | ||
| JP2011500650A5 (enExample) |